Restricted accessLetterFirst published online 2020-12
Editorial Comment on: “Ambulatory-Based Bladder Outlet Procedures Offer Significant Cost Savings and Comparable 30-Day Outcomes Relative to Inpatient Surgery” by Nguyen et al.
NguyenD-D, MarcheseM, OzambelaMD, et al.Ambulatory-based outlet procedures offer significant cost savings and comparable 30-day outcomes relative to inpatient surgery. J Endourology, 2020; 34:1248–1254.
2.
GoreJL, WrightJL, DarathaKB. Hospital-level variation in the quality of urologic cancer surgery. Cancer, 2012; 118:987–996.
3.
NamCS, MehtaA, HammetJ, et al.Variation in practice patterns and reimbursement between female and male urologists for Medicare beneficiaries. JAMA Netw Open, 2009; 2:e198956.
4.
WennbergJE, Cooper M; Dartmouth AtlasMLA. The Dartmouth Atlas of Health Care. Dartmouth: The Center for the Evaluative Clinical Services, Dartmouth Medical School, 1996.
5.
Newgeography: US Urban Area Population 1950-2030. Available at www.newgeography.com (Last accessed August17, 2017).
6.
Loughlin KR The confluence of the aging of the American population and the aging of the urologic workforce: The Parmenides Fallacy. Urol Pract, 2019; 198–203.
7.
CaseA, DentonA. America can afford a world-class health system. Why don't we have one? New York Times. Available at: www.nytimes.com (Last accessed April15, 2020).
8.
6 Trends that will define the future of health care. (CFO Journal) Wall Street J. Available at: www.wsj.com (Last accessed April15, 2020).
9.
HoltgreweHL.American Urological Association Survey of transurethral prostatectomy and the impact of changing Medicare reimbursement. Urol Clin North Am, 1990; 17:587–590.
10.
HoltgreweHL.The medical management of lower urinary tract symptoms and benign prostatic hyperplasia. Urol Clin North Am, 1998; 25:555–569.
11.
HoltgreweHL.The economics of urologic practice in the twenty-first century. Urol Clin North Am, 1998; 25:1–13.
12.
VuichoudC, LoughlinKR. Benign prostatic hyperplasia: Epidemiology, economics and evaluation. Can J Urol, 2015; 22(Suppl. 1):1–6.
13.
GuptaNK, GangerSN, McVaryKT. New and emerging technologies in treatment of lower urinary tract symptoms for benign prostatic hyperplasia. Sex Med Rev, 2019; 7:491–498.
14.
SimmeringJE, TangF, CavanaughJE, et al. The increase in hospitalization for urinary tract infection and the associated costs in the United States, 1998-2011. Open Forum Infect Dis 2017;4 ofw 281.
15.
OsmanT, ElSaeedKO, YoussefHA, et al.Evaluation of the risk factors associated with the development of post-transurethral resection of the prostate and persistent bacteriuria. Arch J Urol, 2017; 15:260–266.
16.
ThorpeKE, JoskiP, JohnstonKJ. Antibiotic resistant infection treatment costs have doubled since 2002, now exceeding $2 billion annually. Health Affairs (Milkwood), 2018; 37:662–669.
